Melanoma Treatment via Sentinel Lymph Node Biomarker Quantification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for melanoma are limited in effectiveness, and there is a need for more targeted approaches to improve treatment outcomes, particularly in addressing the progression and recurrence of the disease.
Innovation Solution
The method involves quantifying RNA expression levels of specific biomarkers such as FOS, NR4A, ITGB1, IRAK3, and Wnt10b in sentinel lymph nodes and administering targeted therapies like immunotherapy, BRAF inhibitors, checkpoint inhibitors, Wnt10b inhibitors, or IRAK3 inhibitors based on the biomarker levels and patient age to tailor treatment strategies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for melanoma are used, then treatment options are available, but treatment effectiveness is limited
Solution Approach 1:
The patent applies local quality by identifying and targeting specific biomarkers (FOS, NR4A, ITGB1, IRAK3, Wnt10b) expressed in specific sentinel lymph nodes to determine personalized treatment approaches. Different biomarker profiles in different lymph nodes lead to customized treatment selections, making the treatment quality local and specific to the patient's unique molecular profile rather than applying a uniform treatment approach.
Solution Approach 2:
The patent utilizes parameter changes by measuring RNA expression levels of specific biomarkers to determine treatment eligibility. The quantitative RNA expression data serves as a parameter that changes the treatment approach - for example, high expression of certain biomarkers may indicate eligibility for immunotherapy or targeted therapies, while low expression may suggest alternative treatment options.
2Measurement precision
If targeted therapies are administered based on biomarker levels, then treatment precision is improved, but treatment complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the treatment decision process into distinct segments based on individual biomarker profiles. Instead of a monolithic treatment protocol, the system segments patients into different treatment groups based on which biomarkers are expressed and at what levels, allowing for manageable complexity in each segment while maintaining overall precision.
Solution Approach 2:
The patent implements feedback by using RNA expression measurement results to guide treatment selection. The measured biomarker levels provide feedback that determines which therapy to administer, creating a closed-loop system where the measurement directly informs the treatment decision, improving precision while the systematic approach to feedback management keeps complexity controlled.
3Productivity
If personalized treatment plans are implemented, then treatment efficacy is enhanced, but implementation complexity increases
Solution Approach 1:
The patent applies universality by establishing a multi-functional biomarker panel that can serve multiple purposes: FOS, NR4A, ITGB1, IRAK3, and Wnt10b expression patterns can indicate different treatment responses, and the same measurement system can be used across different patient populations. This universal panel approach enhances efficacy through personalization while avoiding the complexity of multiple separate assessment systems.
Solution Approach 2:
The patent uses parameter changes by establishing specific RNA expression threshold values and fold-change criteria that translate complex molecular data into actionable treatment decisions. By defining clear parameter cutoffs (such as minimum expression levels or fold changes compared to controls), the system enhances treatment efficacy through personalization while keeping implementation straightforward through objective, measurable criteria.
Data Source
AI summary
Some embodiments of the invention include methods for treating melanoma in a subject. In other embodiments, the methods for treating melanoma in a subject comprise quantifying an RNA expression level for at least one biomarker in a sample (e.g., from a sentinel lymph node of the subject) and administering to the subject a treatment for melanoma (e.g., by administering to the subject immunotherapy, interferon, a BRAF inhibitor, a checkpoint inhibitor, a Wnt10b inhibitor, an IRAK3 inhibitor, or a combination thereof). In still other embodiments, the at least one biomarker can comprise FOS, NR4A, ITGB1, IRAK3, Wnt10b, or a combination thereof. Additional embodiments of the invention are also discussed herein.